Trials / Completed
CompletedNCT06362460
Mass Balance Study of [14C]RAY1216 in Healthy Adult Male Subjects in China
Single-center, Open-label, Non-randomized and Single-dose Clinical Trial to Explore the Mass Balance of Oral Suspension of 400mg [14C]RAY1216
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study is a single-center, open-label, and single-dose clinical study to evaluate the mass balance, biotransformation and pharmacokinetics of \[14C\]RAY1216 in healthy Chinese male participants, revealing the overall pharmacokinetic characteristics of RAY1216.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C] RAY1216 | 400 mg suspension containing 100μCi of \[14C\]RAY1216 |
Timeline
- Start date
- 2023-09-18
- Primary completion
- 2023-11-01
- Completion
- 2023-11-15
- First posted
- 2024-04-12
- Last updated
- 2024-04-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06362460. Inclusion in this directory is not an endorsement.